Related Experiment Video
Updated: Aug 19, 2026
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
Proteomic analysis of nuclear matrix proteins during arsenic trioxide induced apoptosis in leukemia K562 cells
Zi-hui Wang1, Ding Yu, Yan Chen
1Department of Pathology, Beijing University, Shenzhen Hospital, Shenzhen 518036, China. zihuiwang9@hotmail.com
Background:
Arsenic trioxide (As2O3) has been identified as a very potent anti-acute leukemic agent. However its role in apoptosis needs to be elucidated. As2O3 interferes with the proliferation and survival of tumor cells via a variety of mechanisms. Drug-target interactions at the level of nuclear matrix (NM) may be critical events in the induction of cell death by As2O3. This study dealt with As2O3-target interactions at the level of NM in chronic myelogenous leukemia cell line K562 by proteomics.
Methods:
K562 cells were cultured in MEM and treated with different concentrations of As2O3. The nuclear matrix proteins were analyzed by high-resolution two-dimensional gel electrophoresis and computer-assisted image analysis.
Results:
As2O3 significantly inhibited the growth of chronic myelogenous leukemia cell line K562 at low concentrations. While more than 200 protein spots were shared among the nuclear matrices, about 18 distinct spots in the nuclear matrices were found characteristic for As2O3 treated cells.
Conclusions:
As2O3 induces apoptosis in K562 cells in a dose and time-dependent manner. Our results demonstrated that for the detection of the onset of apoptosis, the alteration in the composition of nuclear matrix proteins was a more sensitive indicator than nucleosomal DNA fragmentation test. These results indicated that As2O3 might be clinically useful in the treatment of chronic myelogenous leukemia. The changes of nuclear matrix proteins in the treated cells can be used as a useful indicator for this treatment.
Insights
Arsenic trioxide (As2O3) effectively inhibits chronic myelogenous leukemia (CML) cell growth. Changes in nuclear matrix proteins indicate apoptosis, offering a sensitive marker for As2O3 treatment efficacy in CML.
Area of Science:
- Proteomics
- Cancer Biology
- Cellular Signaling
Background:
- Arsenic trioxide (As2O3) is a potent anti-leukemic agent.
- Its mechanism of action, particularly in apoptosis induction via drug-target interactions within the nuclear matrix (NM), requires further elucidation.
- This study investigates As2O3-NM interactions in K562 cells using proteomics.
Purpose of the Study:
- To investigate the interactions between arsenic trioxide and nuclear matrix proteins in K562 cells.
- To identify specific protein alterations associated with As2O3-induced apoptosis.
- To evaluate the potential of nuclear matrix protein changes as biomarkers for As2O3 treatment in chronic myelogenous leukemia.
Main Methods:
- K562 cells were cultured and treated with varying concentrations of As2O3.
- Nuclear matrix proteins were isolated and analyzed using high-resolution two-dimensional gel electrophoresis.
- Computer-assisted image analysis was employed to identify differential protein expression.
Main Results:
- As2O3 significantly inhibited K562 cell growth at low concentrations.
- Proteomic analysis revealed approximately 18 distinct nuclear matrix protein spots characteristic of As2O3-treated cells, in addition to over 200 common spots.
- Alterations in nuclear matrix protein composition were observed in response to As2O3 treatment.
Conclusions:
- As2O3 induces apoptosis in K562 cells in a dose- and time-dependent manner.
- Changes in nuclear matrix protein composition are a more sensitive indicator of early apoptosis than nucleosomal DNA fragmentation.
- As2O3 shows potential clinical utility for treating chronic myelogenous leukemia, with nuclear matrix protein alterations serving as valuable treatment indicators.
